Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NPC1 | O15118 | 2/20 | 0.77 |
| ▸ | RAB9A | P51151 | 2/20 | 0.77 |
| ▸ | HTR7 | P34969 | 1/20 | 0.67 |
| ▸ | PTPN1 | P18031 | 1/20 | 0.53 |
| ▸ | TSHR | P16473 | 1/20 | 0.51 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.51 |
| ▸ | HTT | P42858 | 1/20 | 0.51 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.51 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.51 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.51 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.50 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.50 |
| ▸ | HTR1A | P08908 | 3/20 | 0.49 |
| ▸ | DRD3 | P35462 | 3/20 | 0.49 |
| ▸ | MEN1 | O00255 | 2/20 | 0.49 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.49 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.49 |
| ▸ | ADRA2A | P08913 | 1/20 | 0.49 |
| ▸ | DRD1 | P21728 | 1/20 | 0.49 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Iodide SCHEMBL21001678 | 0.96 | NPC1 (0.71) | NPC1RAB9AHTR7PTPN1TSHR | |
| Ethylene SCHEMBL7326114 | 0.96 | NPC1 (0.71) | NPC1RAB9AHTR7PTPN1TSHR | |
| Ethylene Glycol SCHEMBL11238423 | 0.94 | NPC1 (0.69) | NPC1RAB9AHTR7PTPN1TSHR | |
| Potassium Iodide SCHEMBL21001677 | 0.94 | NPC1 (0.69) | NPC1RAB9AHTR7PTPN1TSHR | |
| SCHEMBL5663807 | 0.94 | NPC1 (0.74) | NPC1RAB9AHTR7PTPN1TSHR | |
| SCHEMBL5660071 | 0.92 | NPC1 (0.71) | NPC1RAB9AHTR7PTPN1TSHR | |
| SCHEMBL5660315 | 0.92 | NPC1 (0.71) | NPC1RAB9AHTR7PTPN1TSHR | |
| SCHEMBL6614159 | 0.89 | NPC1 (0.67) | NPC1RAB9AHTR7PTPN1TSHR | |
| SCHEMBL117311 | 0.88 | NPC1 (0.69) | NPC1RAB9AHTR7PTPN1TSHR | |
| SCHEMBL9680520 | 0.87 | NPC1 (0.91) | NPC1RAB9AHTR7PTPN1TSHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 576 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-118125969-A | Haloperidol with excellent biological performance and preparation method and application thereof | 湖南洞庭药业股份有限公司 | 2024-06-04 | — | — | CN | claimed |
| US-11655251-B2 | Method for the production of lumateperone and its salts | EGIS GYOGYSZERGYAR ZRT. (HU) | 2023-05-23 | — | — | US | claimed |
| US-20220332716-A1 | SUBSTITUTED HETEROCYCLE FUSED GAMMA-CARBOLINES SYNTHESIS | INTRA-CELLULAR THERAPIES, INC. (US) | 2022-10-20 | — | — | US | claimed |
| US-20220024924-A1 | SOLID STATE FORMS OF LUMATEPERONE SALTS AND PROCESSES FOR PREPARATION OF LUMATEPERONE AND SALTS THEREOF | ASSIA CHEMICAL INDUSTRIES LTD. (IL) | 2022-01-27 | — | — | US | claimed |
| EP-3887374-A2 | SOLID STATE FORMS OF LUMATEPERONE SALTS AND PROCESSES FOR PREPARATION OF LUMATEPERONE AND SALTS THEREOF | Teva Pharmaceuticals International GmbH (CH) | 2021-10-06 | — | — | EP | claimed |
| CN-112538042-A | Preparation method of haloperidol | 湖南洞庭药业股份有限公司 | 2021-03-23 | — | — | CN | claimed |
| US-20210070755-A1 | METHOD FOR THE PRODUCTION OF LUMATEPERONE AND ITS SALTS | EGIS GYOGYSZERGYAR ZRT. (HU) | 2021-03-11 | — | — | US | claimed |
| EP-3717484-A1 | METHOD FOR THE MANUFACTURE OF LUMATEPERONE AND ITS SALTS | Egis Gyógyszergyár Zrt. (HU) | 2020-10-07 | — | — | EP | claimed |
| EP-3663294-A1 | SUBSTITUTED HETEROCYCLE FUSED GAMMA-CARBOLINES SYNTHESIS | Intra-Cellular Therapies, Inc. (US) | 2020-06-10 | — | — | EP | claimed |
| WO-2020112941-A2 | SOLID STATE FORMS OF LUMATEPERONE SALTS AND PROCESSES FOR PREPARATION OF LUMATEPERONE AND SALTS THEREOF | TEVA CZECH INDUSTRIES S.R.O (CZ) | 2020-06-04 | — | — | WO | claimed |
| US-10597395-B2 | Preparation of certain substituted 1-(4-fluorophenyl)-4-(2,3,6b,9,10,10a-hexahydro-1H-pyrido[3′,4′:4,5]pyrrolo[1,2,3-de]quinoxalin-8(7H)-YL)butan-1-ones and pharmaceutically acceptable salts thereof | INTRA-CELLULAR THERAPIES, INC. (US) | 2020-03-24 | — | — | US | claimed |
| US-20200087305-A1 | SUBSTITUTED HETEROCYCLE FUSED GAMMA-CARBOLINES SYNTHESIS | INTRA-CELLULAR THERAPIES, INC. (US) | 2020-03-19 | — | — | US | claimed |
| EP-2134710-B1 | SUBSTITUTED HETEROCYCLE FUSED GAMMA-CARBOLINES SYNTHESIS | INTRA CELLULAR THERAPIES INC (US) | 2020-02-12 | — | — | EP | claimed |
| US-20190218219-A1 | SUBSTITUTED HETEROCYCLE FUSED GAMMA-CARBOLINES SYNTHESIS | INTRA-CELLULAR THERAPIES, INC. (US) | 2019-07-18 | — | — | US | claimed |
| WO-2019102240-A1 | METHOD FOR THE MANUFACTURE OF LUMATEPERONE AND ITS SALTS | EGIS GYÓGYSZERGYÁR ZRT. (HU) | 2019-05-31 | — | — | WO | claimed |
| US-9751883-B2 | Preparation of certain [((6BR,10AS)-2,3,6B,7,8,9,10, 10A-octahydro-1H-pyrido[3′,4′:4,5]pyrrolo [1,2,3-de]quinoxalines and pharmaceutically acceptable salts thereof | INTRA-CELLULAR THERAPIES, INC. (US) | 2017-09-05 | — | — | US | claimed |
| US-9315504-B2 | Preparation of 4-((6BR,10AS)-3-methyl-2,3,6B,9,10, 10A-hexahydro-1H-pyrido[3′,4′:4,5]pyrrolo [1,2,3-de]quinoxalin-8-(7H)-yl)-1-(4-fluorophenyl)-1-butanone or a pharmaceutically acceptable salt thereof | INTRA-CELLULAR THERAPIES, INC. (US) | 2016-04-19 | — | — | US | claimed |
| US-20140364609-A1 | SUBSTITUTED HETEROCYCLE FUSED GAMMA-CARBOLINES SYNTHESIS | INTRA-CELLULAR THERAPIES, INC. | 2014-12-11 | — | — | US | claimed |
| JP-10136993-A | — | — | None | — | — | JP | disclosed |
| US-3890439-A | Imidazolidinone derivatives in the treatment of emesis and psychosomatic disturbances | CIBA GEIGY CORP | 1975-06-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220332716-A1 | SUBSTITUTED HETEROCYCLE FUSED GAMMA-CARBOLINES SYNTHESIS | HCCS, CYCS, CBR3 | NPC1 3361/4885RAB9A 2668/4885HTR7 538/4885 |
| US-20190218219-A1 | SUBSTITUTED HETEROCYCLE FUSED GAMMA-CARBOLINES SYNTHESIS | CYCS, HCCS, IDH3B | NPC1 3036/4885RAB9A 2561/4885HTR7 633/4885 |
| US-20210070755-A1 | METHOD FOR THE PRODUCTION OF LUMATEPERONE AND ITS SALTS | CYP2S1, LSS, CYP26B1 | NPC1 1550/4885RAB9A 2546/4885HTR7 408/4885 |
| US-11655251-B2 | Method for the production of lumateperone and its salts | CYP2S1, LSS, CYP26B1 | NPC1 1558/4885RAB9A 2591/4885HTR7 398/4885 |
| US-20220024924-A1 | SOLID STATE FORMS OF LUMATEPERONE SALTS AND PROCESSES FOR PREPARATION OF LUMATEPERONE AND SALTS THEREOF | RALA, TACR1, SRM | NPC1 3328/4885RAB9A 205/4885HTR7 19/4885 |
| US-10597395-B2 | Preparation of certain substituted 1-(4-fluorophenyl)-4-(2,3,6b,9,10,10a-hexahydro-1H-pyrido[3′,4′:4,5]pyrrolo[1,2,3-de]quinoxalin-8(7H)-YL)butan-1-ones and pharmaceutically acceptable salts thereof | CYP3A7, CYP4B1, CYP1B1 | NPC1 1832/4885RAB9A 397/4885HTR7 117/4885 |
| US-20140364609-A1 | SUBSTITUTED HETEROCYCLE FUSED GAMMA-CARBOLINES SYNTHESIS | HCCS, CYCS, CBR3 | NPC1 3352/4885RAB9A 2645/4885HTR7 633/4885 |
| US-20200087305-A1 | SUBSTITUTED HETEROCYCLE FUSED GAMMA-CARBOLINES SYNTHESIS | HCCS, CYCS, CBR3 | NPC1 3352/4885RAB9A 2645/4885HTR7 633/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.